← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Mbc Pharma, Inc.
Aurora, CO
$6,105,313
Total funding
7
Grants
Funding over time
peak $1.4M · FY2007–18$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$6,105,313 · 7
By mechanism
R44$4,766,765 · 3
R43$1,338,548 · 4
Investigators at Mbc Pharma, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II$1,138,475
R44 · FY2017 · CA
Novel bisphosphonates for prostate cancer therapy$1,070,889
R44 · FY2011 · CA
Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II$860,229
R44 · FY2018 · CA
Novel bisphosphonates for prostate cancer therapy$724,165
R44 · FY2010 · CA
Novel bisphosphonates for multiple myeloma therapy$391,786
R44 · FY2008 · CA
Novel bisphosphonates for multiple myeloma therapy$366,723
R44 · FY2009 · CA
Novel Bone-Targeting Combination Therapy for Osteosarcoma$301,877
R43 · FY2016 · CA
Bone Targeted Antibiotics$300,000
R43 · FY2017 · AI
Bone Targeted Antibiotics$294,202
R43 · FY2018 · AI
Novel Vitamin B6 based prodrugs of gemcitabine$241,512
R43 · FY2013 · CA
Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II$136,623
R44 · FY2018 · CA
Novel Vitamin B6 based prodrugs of gemcitabine$100,957
R43 · FY2014 · CA
Novel bisphosphonates for prostate cancer therapy$100,000
R43 · FY2007 · CA
Novel bisphosphonates for prostate cancer therapy$77,875
R44 · FY2013 · CA